Immunologic and Prognostic Factors Associated with Overall Survival Employing a Poxviral-based PSA Vaccine in Metastatic Castrate-resistant Prostate Cancer

A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine provided evidence of enhanced median overall survival (OS) (p=0.0061) in patients with metastatic castrate-resistant prostate cancer (mCRPC). The study reported here employed the identical vaccine in mCRPC t...

詳細記述

保存先:
書誌詳細
主要な著者: Gulley, James L., Arlen, Philip M., Madan, Ravi A., Tsang, Kwong-Yok, Pazdur, Mary P., Skarupa, Lisa, Jones, Jacquin L., Poole, Diane J., Higgins, Jack P., Hodge, James W., Cereda, Vittore, Vergati, Matteo, Steinberg, Seth M., Halabi, Susan, Jones, Elizabeth, Chen, Clara, Parnes, Howard, Wright, John J., Dahut, William L., Schlom, Jeffrey
フォーマット: Artigo
言語:Inglês
出版事項: 2009
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2832083/
https://ncbi.nlm.nih.gov/pubmed/19890632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-009-0782-8
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料